Diagnostic Electrocardiography Pipeline
Innovative diagnostic tools for detecting rare and hidden disease, based on the world’s largest labeled patient dataset, built to be integrated into existing physician workflows and currently pursuing FDA approval.
ECG-AI™ LEF
FDA Breakthrough Device Designation; FDA Cleared
Phase: Market Authorization
Pulmonary Hypertension
Granted FDA Breakthrough Device Designation
Phase: Validation
Cardiac Amyloidosis
Granted FDA Breakthrough Device Designation
Phase: Validation
Hyperkalemia
Granted FDA Breakthrough Device Designation
Phase: Pre-Submission
Atrial Fibrillation in Normal Sinus Rhythm
Phase: Pre-Submission
Hypertrophic Cardiomyopathy (HCM)
Phase: Development
Myocarditis
Phase: Development
Aortic Stenosis
Phase: Development
Early Stage Development Programs
Phase: Development
Electrophysiology Pipeline
Anumana has a highly fertile portfolio of EP applications under development, aiming to increase procedure accuracy, reduce procedure time, and improve patient safety and outcomes.
Electro-anatomical Mapping
FDA Cleared
Phase: Market Authorization
Pulmonary Vein Potential Identification
Phase: Development
Ventricular Tachycardia Identification
Phase: Development
Supraventricular Tachycardia Identification
Phase: Development
Early Stage Development Programs
Phase: Development
Download Our One-Pager
Featuring key corporate highlights and an overview of Anumana's technology
@2024 anumana, Inc. All rights reserved.